Erica Schwartz CDC confirmation hearing
Analysis based on 66 articles · First reported Jul 15, 2026 · Last updated Jul 30, 2026
The confirmation hearing underscores ongoing political interference at the CDC, which may erode public trust and hamper pandemic response, potentially affecting healthcare and pharmaceutical sectors. Uncertainty about the agency's independence could weigh on vaccine-related stocks and public health investments.
Dr. Erica Schwartz, nominated by President Donald Trump to lead the United States — Centers for Disease Control and Prevention (CDC), appeared before the Senate Health, Education, Labor and Pensions Committee for her confirmation hearing on July 15, 2026. Schwartz, a retired rear admiral and former deputy surgeon general, pledged to 'never betray the science' and use 'radical transparency' to rebuild public trust. However, she declined to commit to reversing certain actions by Health Secretary Robert F. Kennedy Jr., including a directive to suspend a flu vaccination campaign and the removal of a CDC website linking vaccines to autism. The CDC has been in turmoil, losing over 3,000 employees since Trump returned to office, with a revolving door of leaders. Schwartz's nomination is the third attempt to fill the role permanently. Also at the hearing, Sean Kaufman faced questions for his nomination as Assistant Secretary for Preparedness and Response, including his past anti-vaccine comments and support for canceling mRNA vaccine projects.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard